China’s latest NRDL update continues to exclude foreign PD-1 inhibitors, favours rare disease drugs
China’s much-anticipated update of its National Reimbursement Drug List (NRDL) presents a mixed bag for overseas pharma. Overall, there were few surprises in China’s continued prioritisation…
By